Lazertinib
According to the NCI website, Lazertinib is an orally available third-generation, selective inhibitor of certain forms of the epidermal growth factor receptor (EGFR) with activating mutations. Check for active clinical trials using this agent. (NCI Thesaurus)
More Information in English:
Link to Drug Information Portal, a service of the U.S. National Library of Medicine, National Institutes of Health
Link to National Cancer Institute